Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06803771 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surveillance of Pancreatic Health After Diabetes Diagnosis

Study acronym: SAFE-D
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Feb 28, 2028 → Jul 29, 2029
Primary endpoint removed 3 → 2 primary endpoints
Enrollment reduced 67% 15000 → 5000 participants
See other at-risk trials from University Hospital Southampton NHS Foundation Trust

Record History

  1. Primary completion pushed from Feb 28, 2028 to Jul 29, 2029 Primary endpoint(s) modified · Enrollment reduced: 15000 → 5000 participants · Completion pushed from Feb 2029 to Jul 2032 · 2 more Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment reduced: 15000 → 5000 participants
    • Completion pushed from Feb 2029 to Jul 2032
    • Trial arms changed: 2 → 1
    • Site details revised at 1 of 31 sites
  2. Enrollment target: 15000 to 5000 Primary completion date: Feb 28, 2028 to Jul 29, 2029 · Primary endpoints: 3 to 2 · Completion date: Feb 2029 to Jul 2032 · 5 more Show 8 more changesShow less
    • Primary completion date: Feb 28, 2028 to Jul 29, 2029
    • Primary endpoints: 3 to 2
    • Completion date: Feb 2029 to Jul 2032
    • Eligibility criteria expanded, about 53 words
    • Secondary endpoints: 4 to 5
    • Study description shortened, about 28 words
    • Site details revised at 11 of 31 sites
    • Study arms: 2 to 1
  3. Study sites: 14 to 31v3
  4. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Feb 28, 2031 to Feb 28, 2028 · Study sites: 0 to 14 · Completion date: Feb 29, 2032 to Feb 2029 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Feb 28, 2031 to Feb 28, 2028
    • Study sites: 0 to 14
    • Completion date: Feb 29, 2032 to Feb 2029
    • Start date changed from estimate of Mar 3, 2025 to May 21, 2025
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.
Trial Details
NCT Number NCT06803771
Lead Sponsor University Hospital Southampton NHS Foundation Trust
Collaborators: ClearNote Health
Conditions Diabetes Mellitus, Pancreatic Cancer, Adult
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov